Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology
Back to News
AlphaMaven Alternative Investment News
Hedge Fund

Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology

dealbreaker
3 months ago
50 views
A patent dispute over technology key to messenger RNA Covid-19 vaccines is settling with Moderna agreeing to pay $950 million up front and potentially more than $1 billion later, a resolution that comes days before the expected trial start in litigation that has been brewing for years.The cash will go to Arbutus Biopharma and Genevant Sciences, companies in which Roivant Sciences holds ownership stakes. Moderna retains the right to appeal a narrow legal matter. But to Roivant CEO Matt Gline, the...

Continue Reading

Sign up for FREE to read the full article and access 133K+ alternative investment headlines.

Create Free Account Login

Not a member yet?

Why AlphaMaven

The Premier Alternative
Investment Platform

Research & Due Diligence for Qualified Investors

Free Membership for Qualified Investors & Industry Participants
Personalized Content
Breaking News 24/7
Daily Newsletter & Indices
Investment Listings
Company & Contact Directory
Member Publications
Alpha University Videos
AUM Accelerator Program
Due Diligence, Webinars, Events & LeaderBoards
145K+
News & Posts
24K+
Investor Profiles
24/7
Coverage
Sign Up Now

ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.

© 2026 Maven Data Group, Inc.